{"id":685254,"date":"2024-01-22T14:20:02","date_gmt":"2024-01-22T14:20:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=685254"},"modified":"2024-01-22T14:20:02","modified_gmt":"2024-01-22T14:20:02","slug":"tcell-lymphoma-pipeline-updates-fda-approvals-clinical-trials-therapies-mechanism-of-action-route-of-administration-by-delveinsight-jazz-pharmaceuticals-genor-biopharma-solasia-pharma","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/tcell-lymphoma-pipeline-updates-fda-approvals-clinical-trials-therapies-mechanism-of-action-route-of-administration-by-delveinsight-jazz-pharmaceuticals-genor-biopharma-solasia-pharma_685254.html","title":{"rendered":"T-Cell Lymphoma Pipeline (Updates): FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Jazz Pharmaceuticals, Genor Biopharma, Solasia Pharma"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1705896763.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"T-Cell Lymphoma Pipeline (Updates): FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Jazz Pharmaceuticals, Genor Biopharma, Solasia Pharma\" src=\"https:\/\/www.abnewswire.com\/uploads\/1705896763.jpeg\" alt=\"T-Cell Lymphoma Pipeline (Updates): FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Jazz Pharmaceuticals, Genor Biopharma, Solasia Pharma\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>T-Cell Lymphoma Pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">(Albany, USA) DelveInsight&rsquo;s, &ldquo;<strong>T-Cell Lymphoma Pipeline Insight, 2023<\/strong>&rdquo; report provides comprehensive insights about <strong>85+ companies and 85+ pipeline drugs<\/strong> in T-Cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To know more about T-Cell Lymphoma pipeline report, click here @ <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/t-cell-lymphoma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>T-Cell Lymphoma Drugs in different phases<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some facts of the T-Cell Lymphoma Pipeline report are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>DelveInsight Evaluates a Robust T-Cell Lymphoma Pipeline as 120+ Influential Pharma Players to Set Foot in the Domain<\/li>\n<li>Leading T-Cell Lymphoma companies working in the market are Jazz Pharmaceuticals, Genor Biopharma, Solasia Pharma, Celgene, Celleron Therapeutics, Seagen, Nanjing Sanhome Pharmaceutical, Merck Sharp &amp; Dohme, Medevir, Bristol Myers Squibb, Pfizer, Innate Pharma, Dizal Pharmaceutical, Hoffman-La-Roche, Affirmed, ImmuneOncia Therapeutics, CerRx, Shandong New Time Pharmaceutical, Secura Bio, Janssen Biotech, CStone Pharmaceutical, Galderma, Bioniz, Portola Pharmaceuticals, VidacPharma, Celgene Corporation, Shanghai Yingli Pharmaceutical, ViGenCell, Daiichi Sankyo, Chia Tai Tianqing Pharmaceutical Group, BeiGene, Kura Oncology, Rafael Pharmaceuticals, Eutilex, Yake Biotechnology, Rhizen Pharmaceuticals, Eli Lilly and Company, Onyx Pharmaceuticals, Astex Therapeutics, Aileron Therapeutics, Autolus, Akeso Biopharma, AVM Biotechnology, Ayala Pharmaceuticals, Trillium Therapeutics and others.<\/li>\n<li>Some of the T-Cell Lymphoma Drugs are SP-02, CC-486, IMC-001, Geptanolimab, Daratumumab, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for a sample to know more about the T-Cell Lymphoma clinical trial advancements @ <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/t-cell-lymphoma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>https:\/\/www.delveinsight.com\/sample-request\/t-cell-lymphoma-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>T-Cell Lymphoma Overview:<\/strong><\/p>\n<p style=\"text-align: justify;\">T cell lymphomas (TCL) are a very heterogeneous group of lymphoid malignancies derived from mature T cells differing by localization, pathological features, and clinical presentation. T-Cell Lymphomas can develop in lymphoid tissues such as the lymph nodes and spleen or outside of lymphoid tissues (i.e., gastrointestinal tract, liver, nasal cavity, skin, and others).&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>T-Cell Lymphoma Emerging Drugs<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>SP-02: Solasia Pharma<\/strong><\/p>\n<p style=\"text-align: justify;\">SP-02 (Darinaparsin) is a novel mitochondrial-targeted agent (organoarsenic) being developed for the treatment of various hematologic and solid cancers. In a US Phase II study, darinaparsin demonstrated clinical activity evidence in lymphoma, particularly PTCL. Furthermore, the Phase I study done in the US and the Pan-Asian Phase 1 study demonstrated positive efficacy and safety of SP-02. The drug is currently being evaluated in Phase III clinical trials to treat patients with Peripheral T Cell Lymphoma. Solasia has begun preparing for the NDA Filing of SP-02.<\/p>\n<p style=\"text-align: justify;\"><strong>CC-486: Celgene<\/strong><\/p>\n<p style=\"text-align: justify;\">CC-486 (Azacitidine) is an orally-active form of Vidaza, a chemical analog of the cytosine nucleoside used in DNA and RNA. The main mechanism of action is thought to be hypomethylation of DNA and direct cytotoxicity to abnormal hematopoietic cells in the bone marrow. Hypomethylation may restore normal function to genes that are critical for differentiation and proliferation. CC-486 is indicated for the treatment of acute myeloid leukemia in first remission. The drug is in Phase III clinical studies for the treatment of T-Cell Lymphoma.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for a sample to get detailed analysis of T-Cell Lymphoma therapies, click here@ <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/t-cell-lymphoma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>https:\/\/www.delveinsight.com\/sample-request\/t-cell-lymphoma-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>T-Cell Lymphoma Pipeline Therapeutic Assessment<\/strong><\/p>\n<p style=\"text-align: justify;\">There are approx.&nbsp;85+ key companies&nbsp;which are developing the therapies for T-Cell Lymphoma. The companies which have their T-Cell Lymphoma drug candidates in the most advanced stage, i.e. phase III include,&nbsp;Solasia Pharma and others.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the T-Cell Lymphoma Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<li>T-Cell Lymphoma Pipeline Assessment: Product Type, Molecule Type, Mechanism of Action, Route of Administration<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li>T-Cell Lymphoma Companies<strong>&ndash;&nbsp;<\/strong>Jazz Pharmaceuticals, Genor Biopharma, Solasia Pharma, Celgene, Celleron Therapeutics, Seagen, Nanjing Sanhome Pharmaceutical, Merck Sharp &amp; Dohme, Medevir, Bristol Myers Squibb, Pfizer, Innate Pharma, Dizal Pharmaceutical, Hoffman-La-Roche, Affirmed, ImmuneOncia Therapeutics, CerRx, Shandong New Time Pharmaceutical, Secura Bio, Janssen Biotech, CStone Pharmaceutical, Galderma, Bioniz, Portola Pharmaceuticals, VidacPharma, Celgene Corporation, Shanghai Yingli Pharmaceutical, ViGenCell, Daiichi Sankyo, Chia Tai Tianqing Pharmaceutical Group, BeiGene, Kura Oncology, Rafael Pharmaceuticals, Eutilex, Yake Biotechnology, Rhizen Pharmaceuticals, Eli Lilly and Company, Onyx Pharmaceuticals, Astex Therapeutics, Aileron Therapeutics, Autolus, Akeso Biopharma, AVM Biotechnology, Ayala Pharmaceuticals, Trillium Therapeutics and others.<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li>T-Cell Lymphoma Pipeline Therapies- SP-02, CC-486, IMC-001, Geptanolimab, Daratumumab, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Learn more about the emerging T-Cell Lymphoma pipeline therapies @&nbsp;T-Cell Lymphoma Clinical Trials Analysis &#8211; <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/t-cell-lymphoma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>https:\/\/www.delveinsight.com\/sample-request\/t-cell-lymphoma-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\">Introduction<\/p>\n<p style=\"text-align: justify;\">Executive Summary<\/p>\n<p style=\"text-align: justify;\">T-Cell Lymphoma: Overview<\/p>\n<ul style=\"text-align: justify;\">\n<li>Causes<\/li>\n<li>Mechanism of Action<\/li>\n<li>Signs and Symptoms<\/li>\n<li>Diagnosis<\/li>\n<li>Disease Management<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">T-Cell Lymphoma&nbsp;Pipeline Therapeutics<\/p>\n<ul style=\"text-align: justify;\">\n<li>Comparative Analysis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">T-Cell Lymphoma&nbsp;Therapeutic Assessment<\/p>\n<ul style=\"text-align: justify;\">\n<li>Assessment by Product Type<\/li>\n<li>Assessment by Stage and Product Type<\/li>\n<li>Assessment by Route of Administration<\/li>\n<li>Assessment by Stage and Route of Administration<\/li>\n<li>Assessment by Molecule Type<\/li>\n<li>Assessment by Stage and Molecule Type<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Late Stage Products (Pre-registration)<\/p>\n<ul style=\"text-align: justify;\">\n<li>Comparative Analysis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Geptanolimab: Genor Biopharma<\/p>\n<ul style=\"text-align: justify;\">\n<li>Product Description<\/li>\n<li>Research and Development<\/li>\n<li>Product Development Activities<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Late Stage Products (Phase III)<\/p>\n<ul style=\"text-align: justify;\">\n<li>Comparative Analysis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">SP-02: Solasia Pharma<\/p>\n<ul style=\"text-align: justify;\">\n<li>Product Description<\/li>\n<li>Research and Development<\/li>\n<li>Product Development Activities<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Mid Stage Products (Phase II)<\/p>\n<ul style=\"text-align: justify;\">\n<li>Comparative Analysis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">IMC-001: ImmuneOncia Therapeutics<\/p>\n<ul style=\"text-align: justify;\">\n<li>Product Description<\/li>\n<li>Research and Development<\/li>\n<li>Product Development Activities<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Early Stage Products (Phase I\/II)<\/p>\n<ul style=\"text-align: justify;\">\n<li>Comparative Analysis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Tolinapant: Astex Pharmaceuticals<\/p>\n<ul style=\"text-align: justify;\">\n<li>Product Description<\/li>\n<li>Research and Development<\/li>\n<li>Product Development Activities<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">T-Cell Lymphoma&nbsp;Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Early Stage Products (Phase I)<\/p>\n<ul style=\"text-align: justify;\">\n<li>Comparative Analysis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">TTI-621: Trillium Therapeutics<\/p>\n<ul style=\"text-align: justify;\">\n<li>Product Description<\/li>\n<li>Research and Development<\/li>\n<li>Product Development Activities<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Preclinical and Discovery Stage Products<\/p>\n<ul style=\"text-align: justify;\">\n<li>Comparative Analysis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">BBI 3000: Brickell Biotech Inc<\/p>\n<ul style=\"text-align: justify;\">\n<li>Product Description<\/li>\n<li>Research and Development<\/li>\n<li>Product Development Activities<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Inactive Products<\/p>\n<ul style=\"text-align: justify;\">\n<li>Comparative Analysis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">T-Cell Lymphoma Key Companies<\/p>\n<p style=\"text-align: justify;\">T-Cell Lymphoma Key Products<\/p>\n<p style=\"text-align: justify;\">T-Cell Lymphoma- Unmet Needs<\/p>\n<p style=\"text-align: justify;\">T-Cell Lymphoma Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">T-Cell Lymphoma Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify;\">T-Cell Lymphoma Analyst Views<\/p>\n<p style=\"text-align: justify;\">T-Cell Lymphoma Key Companies<\/p>\n<p style=\"text-align: justify;\">Appendix<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free sample @ <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/t-cell-lymphoma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>https:\/\/www.delveinsight.com\/sample-request\/t-cell-lymphoma-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&amp;D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers &amp; Acquisitions.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=tcell-lymphoma-pipeline-updates-fda-approvals-clinical-trials-therapies-mechanism-of-action-route-of-administration-by-delveinsight-jazz-pharmaceuticals-genor-biopharma-solasia-pharma\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +91-9650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/conference-coverage-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/conference-coverage-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/conference-coverage-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=tcell-lymphoma-pipeline-updates-fda-approvals-clinical-trials-therapies-mechanism-of-action-route-of-administration-by-delveinsight-jazz-pharmaceuticals-genor-biopharma-solasia-pharma\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>T-Cell Lymphoma Pipeline (Albany, USA) DelveInsight&rsquo;s, &ldquo;T-Cell Lymphoma Pipeline Insight, 2023&rdquo; report provides comprehensive insights about 85+ companies and 85+ pipeline drugs in T-Cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/tcell-lymphoma-pipeline-updates-fda-approvals-clinical-trials-therapies-mechanism-of-action-route-of-administration-by-delveinsight-jazz-pharmaceuticals-genor-biopharma-solasia-pharma_685254.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,413],"tags":[],"class_list":["post-685254","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/685254","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=685254"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/685254\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=685254"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=685254"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=685254"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}